Targeting cytoskeleton reorganisation as antimetastatic treatment

Clinical and Translational Oncology

Volumn 12, Issue 10, 2010, Pages 662-669

  Quintela Fandino, Miguel ^a   González Martín, Antonio ^a   Colomer, Ramon ^a  

^a MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Actin polymerization; Cofilin; Cytoskeleton reorganization; FAK; Metastasis; Src

Indexed keywords

2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BOSUTINIB; COFILIN; COFILIN 1; DASATINIB; FASUDIL; FLICE INHIBITORY PROTEIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; G ACTIN; G PROTEIN COUPLED RECEPTOR; GSK 2256098; LIM KINASE 1; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; P21 ACTIVATED KINASE; PF 04554878; PF 271; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN CDC42; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SU 6566; TAC 554; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; AUTOPHOSPHORYLATION; BREAST CANCER; CLINICAL TRIAL; CYTOSKELETON; DEPOLYMERIZATION; DIARRHEA; DRUG TOLERABILITY; ENZYME ACTIVATION; FATIGUE; FEBRILE NEUTROPENIA; FILOPODIUM; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TUMOR; HUMAN; KIDNEY FAILURE; LEUKEMIA; LYMPHOCYTOPENIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MICROFILAMENT; MIGRAINE; NAUSEA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOSKELETON; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; RESEARCH DESIGN; SIGNAL TRANSDUCTION;

EID: 78649660795     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0575-8     Document Type: Review

References (116)

1. G. Christofori 2006 New signals from the invasive front Nature 441 444 450 1:CAS:528:DC%2BD28XkvVyrsro%3D 16724056
2. J.M. Llovet S. Ricci V. Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
3. R.J. Motzer T.E. Hutson P. Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529
4. K. Miller M. Wang J. Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
5. T.J. Lynch D.W. Bell R. Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 1:CAS:528: DC%2BD2cXktF2js7c%3D 15118073
6. B.J. Druker C.L. Sawyers H. Kantarjian, et al. 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 1038 1042 1:CAS:528:DC%2BD3MXivFGnu7o%3D 11287973
7. B.J. Druker M. Talpaz D.J. Resta, et al. 2001 Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 1:CAS:528:DC%2BD3MXivFGnu70%3D 11287972
8. A.F. Chambers A.C. Groom I.C. MacDonald 2002 Dissemination and growth of cancer cells in metastatic sites Nat Rev Cancer 2 563 572 1:CAS:528: DC%2BD38XlslGqsLw%3D 12154349
9. B. Boyer G.C. Tucker A.M. Valles, et al. 1989 Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells J Cell Biol 109 1495 1509 1:CAS:528:DyaL1MXlvFahtrs%3D 2677020
10. W. Wang R. Eddy J. Condeelis 2007 The cofilin pathway in breast cancer invasion and metastasis Nat Rev Cancer 7 429 440 1:CAS:528:DC%2BD2sXls1KjsLw%3D 17522712
11. W. Wang J.B. Wyckoff S. Goswami, et al. 2007 Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors Cancer Res 67 3505 3511 1:CAS:528:DC%2BD2sXkt1KjtLc%3D 17440055
12. W. Wang S. Goswami E. Sahai, et al. 2005 Tumor cells caught in the act of invading: their strategy for enhanced cell motility Trends Cell Biol 15 138 145 1:CAS:528:DC%2BD2MXitVeitrc%3D 15752977
13. S. Ono 2007 Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics Int Rev Cytol 258 1 82 1:CAS:528:DC%2BD2sXmtFKltbk%3D 17338919
14. Maciver SK, Hussey PJ (2002) The ADF/cofilin family: actin-remodeling proteins. Genome Biol 3:reviews3007
15. M. Ghosh X. Song G. Mouneimne, et al. 2004 Cofilin promotes actin polymerization and defines the direction of cell motility Science 304 743 746 1:CAS:528:DC%2BD2cXjsV2gtLg%3D 15118165
16. P. Hotulainen E. Paunola M.K. Vartiainen, et al. 2005 Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells Mol Biol Cell 16 649 664 1:CAS:528:DC%2BD2MXhtVGitLg%3D 15548599
17. A. Mogilner G. Oster 2003 Polymer motors: pushing out the front and pulling up the back Curr Biol 13 R721 733 1:CAS:528:DC%2BD3sXnsVKku7g%3D 13678614
18. C.G. dos Remedios D. Chhabra M. Kekic, et al. 2003 Actin binding proteins: regulation of cytoskeletal microfilaments Physiol Rev 83 433 473 12663865
19. H. Yamaguchi M. Lorenz S. Kempiak, et al. 2005 Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin J Cell Biol 168 441 452 1:CAS:528:DC%2BD2MXhtVWktLc%3D 15684033
20. W. Wang G. Mouneimne M. Sidani, et al. 2006 The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors J Cell Biol 173 395 404 1:CAS:528:DC%2BD28Xks1OjsLs%3D 16651380
21. I. Ichetovkin J. Han K.M. Pang, et al. 2000 Actin filaments are severed by both native and recombinant dictyostelium cofilin but to different extents Cell Motil Cytoskeleton 45 293 306 1:CAS:528:DC%2BD3cXivVSqtrw%3D 10744862
22. I. Ichetovkin W. Grant J. Condeelis 2002 Cofilin produces newly polymerized actin filaments that are preferred for dendritic nucleation by the Arp2/3 complex Curr Biol 12 79 84 1:CAS:528:DC%2BD38Xpt1artA%3D%3D 11790308
23. E. Andrianantoandro T.D. Pollard 2006 Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin Mol Cell 24 13 23 1:CAS:528:DC%2BD28XhtFegtbrJ 17018289
24. J.R. Bamburg O.P. Wiggan 2002 ADF/cofilin and actin dynamics in disease Trends Cell Biol 12 598 605 1:CAS:528:DC%2BD38XpsV2mtr0%3D 12495849
25. C. Dan A. Kelly O. Bernard, et al. 2001 Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin J Biol Chem 276 32115 32121 1:CAS:528:DC%2BD3MXms1SmtLo%3D 11413130
26. I. Okano J. Hiraoka H. Otera, et al. 1995 Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs J Biol Chem 270 31321 31330 1:CAS:528:DyaK28XivFWhug%3D%3D 8537403
27. N. Yang O. Higuchi K. Ohashi, et al. 1998 Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization Nature 393 809 812 1:CAS:528:DyaK1cXktl2jtbo%3D 9655398
28. J. Toshima J.Y. Toshima K. Takeuchi, et al. 2001 Cofilin phosphorylation and actin reorganization activities of testicular protein kinase 2 and its predominant expression in testicular Sertoli cells J Biol Chem 276 31449 31458 1:CAS:528:DC%2BD3MXmsVejtro%3D 11418599 (Pubitemid 37385018)
29. J. Toshima J.Y. Toshima T. Amano, et al. 2001 Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation Mol Biol Cell 12 1131 1145 1:CAS:528:DC%2BD3MXjtVaqtr0%3D 11294912 (Pubitemid 33052004)
30. R. Niwa K. Nagata-Ohashi M. Takeichi, et al. 2002 Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin Cell 108 233 246 1:CAS:528:DC%2BD38XhtV2hsbo%3D 11832213
31. P.J. Meberg S. Ono L.S. Minamide, et al. 1998 Actin depolymerizing factor and cofilin phosphorylation dynamics: response to signals that regulate neurite extension Cell Motil Cytoskeleton 39 172 190 1:CAS:528:DyaK1cXhtFSqur8%3D 9484959
32. A. Ambach J. Saunus M. Konstandin, et al. 2000 The serine phosphatases PP1 and PP2A associate with and activate the actin-binding protein cofilin in human T lymphocytes Eur J Immunol 30 3422 3431 1:CAS:528:DC%2BD3MXpt1Kr 11093160
33. A. Gohla J. Birkenfeld G.M. Bokoch 2005 Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics Nat Cell Biol 7 21 29 1:CAS:528:DC%2BD2MXlvFSm 15580268
34. Y. Goldberg 1999 Protein phosphatase 2A: who shall regulate the regulator? Biochem Pharmacol 57 321 328 1:CAS:528:DyaK1MXmt1Khtw%3D%3D 9933020
35. V. Janssens J. Goris 2001 Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling Biochem J 353 417 439 1:CAS:528:DC%2BD3MXhtlOrs70%3D 11171037
36. N. Yonezawa Y. Homma I. Yahara, et al. 1991 A short sequence responsible for both phosphoinositide binding and actin binding activities of cofilin J Biol Chem 266 17218 17221 1:CAS:528:DyaK3MXltlShur0%3D 1654325
37. N. Yonezawa E. Nishida K. Iida, et al. 1990 Inhibition of the interactions of cofilin, destrin, and deoxyribonuclease I with actin by phosphoinositides J Biol Chem 265 8382 8386 1:CAS:528:DyaK3cXktlKktro%3D 2160454
38. G. Mouneimne V. DesMarais M. Sidani, et al. 2006 Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis Curr Biol 16 2193 2205 1:CAS:528:DC%2BD28Xht1CmtL%2FK 17113383
39. P. Devreotes C. Janetopoulos 2003 Eukaryotic chemotaxis: distinctions between directional sensing and polarization J Biol Chem 278 20445 20448 1:CAS:528:DC%2BD3sXkt1Wjtb4%3D 12672811
40. M.D. Schaller 2001 Biochemical signals and biological responses elicited by the focal adhesion kinase Biochim Biophys Acta 1540 1 21 1:CAS:528: DC%2BD3MXltlKqt7g%3D 11476890
41. D.A. Hsia S.T. Lim J.A. Bernard-Trifilo, et al. 2005 Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src Mol Cell Biol 25 9700 9712 1:CAS:528:DC%2BD2MXhtFOns7%2FI 16227616
42. S.K. Mitra D.A. Hanson D.D. Schlaepfer 2005 Focal adhesion kinase: in command and control of cell motility Nat Rev Mol Cell Biol 6 56 68 1:CAS:528:DC%2BD2MXlvVWm 15688067
43. A. Angelucci M. Bologna 2007 Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family Curr Pharm Des 13 2129 2145 1:CAS:528: DC%2BD2sXovFalsrg%3D 17627545
44. J. Schwock N. Dhani D.W. Hedley 2010 Targeting focal adhesion kinase signaling in tumor growth and metastasis Expert Opin Ther Targets 14 77 94 1:CAS:528:DC%2BD1MXhsFCitbvM 20001212
45. E. Avizienyte A.W. Wyke R.J. Jones, et al. 2002 Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling Nat Cell Biol 4 632 638 1:CAS:528:DC%2BD38Xls1OrtLk%3D 12134161
46. C. Cicchini I. Laudadio F. Citarella, et al. 2008 TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling Exp Cell Res 314 143 152 1:CAS:528:DC%2BD2sXhtlyrtrvN 17949712
47. M.J. van Nimwegen S. Verkoeijen L. van Buren, et al. 2005 Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation Cancer Res 65 4698 4706 15930288
48. S.A. Mani W. Guo M.J. Liao, et al. 2008 The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 704 715 1:CAS:528:DC%2BD1cXmsVOru7w%3D 18485877
49. M. Luo H. Fan T. Nagy, et al. 2009 Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells Cancer Res 69 466 474 1:CAS:528: DC%2BD1MXltFSisw%3D%3D 19147559
50. M. Luo J.L. Guan 2010 Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis Cancer Lett 289 127 139 1:CAS:528:DC%2BC3cXis1WltLg%3D 19643531
51. J.K. Slack-Davis K.H. Martin R.W. Tilghman, et al. 2007 Cellular characterization of a novel focal adhesion kinase inhibitor J Biol Chem 282 14845 14852 1:CAS:528:DC%2BD2sXltFemtbY%3D 17395594
52. W.G. Roberts E. Ung P. Whalen, et al. 2008 Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271 Cancer Res 68 1935 1944 1:CAS:528:DC%2BD1cXjtFOhtrw%3D 18339875
53. L.L. Siu H.A. Burris L. Mileshkin, et al. 2007 Phase I study of focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 25 3527
54. A study of PF-04554878 in patients with advanced non-hematologic malignancies (B0761001). http://clinicaltrials.gov/ct2/show/NCT00787033?term= FAK+inhibitor&rank=3
55. E.A. Beierle A. Trujillo A. Nagaram, et al. 2008 TAE226 inhibits human neuroblastoma cell survival Cancer Invest 26 145 151 1:CAS:528: DC%2BD1cXhs1WnsrY%3D 18259944
56. V.M. Golubovskaya C. Virnig W.G. Cance 2008 TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR Mol Carcinog 47 222 234 1:CAS:528:DC%2BD1cXjslCit7c%3D 17849451
57. K. Sakurama K. Noma M. Takaoka, et al. 2009 Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor Mol Cancer Ther 8 127 134 1:CAS:528: DC%2BD1MXjvFSmsw%3D%3D 19139121
58. Study of a focal adhesion kinase inhibitor in subjects with solid tumors. http://clinicaltrials.gov/ct2/show/NCT01138033?term=FAK+inhibitor&rank=1
59. D.J. Sieg C.R. Hauck D. Ilic, et al. 2000 FAK integrates growth-factor and integrin signals to promote cell migration Nat Cell Biol 2 249 256 1:CAS:528:DC%2BD3cXktlOqs7o%3D 10806474
60. N.O. Carragher S.M. Walker L.A. Scott Carragher, et al. 2006 Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function Oncogene 25 5726 5740 1:CAS:528: DC%2BD28Xpsl2rurY%3D 16652152
61. J.S. Biscardi D.A. Tice S.J. Parsons 1999 c-Src, receptor tyrosine kinases, and human cancer Adv Cancer Res 76 61 119 1:CAS:528:DyaK1MXjtFKgsLw%3D 10218099
62. R. Jove H. Hanafusa 1987 Cell transformation by the viral src oncogene Annu Rev Cell Biol 3 31 56 1:CAS:528:DyaL1cXltVSmsQ%3D%3D 2446642
63. E. Wang A.R. Goldberg 1976 Changes in microfilament organization and surface topography upon transformation of chick embryo fibroblasts with Rous sarcoma virus Proc Natl Acad Sci U S A 73 4065 4069 1:STN:280: DyaE2s%2FlvVSltQ%3D%3D 186784
64. J.T. Parsons M.J. Weber 1989 Genetics of src: structure and functional organization of a protein tyrosine kinase Curr Top Microbiol Immunol 147 79 127 1:STN:280:DyaK3c7ltFansA%3D%3D 2482802
65. J.D. Bjorge A. Jakymiw D.J. Fujita 2000 Selected glimpses into the activation and function of Src kinase Oncogene 19 5620 5635 1:CAS:528: DC%2BD3cXosl2nuro%3D 11114743
66. C.M. Laukaitis D.J. Webb K. Donais, et al. 2001 Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells J Cell Biol 153 1427 1440 1:CAS:528: DC%2BD3MXkslensLk%3D 11425873
67. M. Guarino 2010 Src signaling in cancer invasion J Cell Physiol 223 14 26 1:CAS:528:DC%2BC3cXhtlSit70%3D 20049846
68. M. Guarino 1995 Epithelial-to-mesenchymal change of differentiation. From embryogenetic mechanism to pathological patterns Histol Histopathol 10 171 184 1:STN:280:DyaK2M3ns1emuw%3D%3D 7756736
69. M. Guarino 2007 Epithelial-mesenchymal transition and tumour invasion Int J Biochem Cell Biol 39 2153 2160 1:CAS:528:DC%2BD2sXhtFWgsL%2FP 17825600
70. M. Guarino B. Rubino G. Ballabio 2007 The role of epithelial-mesenchymal transition in cancer pathology Pathology 39 305 318 1:CAS:528: DC%2BD2sXmt1ant7o%3D 17558857
71. J. Behrens L. Vakaet R. Friis, et al. 1993 Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene J Cell Biol 120 757 766 1:CAS:528: DyaK3sXnvVaqtA%3D%3D 8425900
72. G. Niu T. Bowman M. Huang, et al. 2002 Roles of activated Src and Stat3 signaling in melanoma tumor cell growth Oncogene 21 7001 7010 1:CAS:528:DC%2BD38XnsFylur0%3D 12370822
73. R.L. Malek R.B. Irby Q.M. Guo, et al. 2002 Identification of Src transformation fingerprint in human colon cancer Oncogene 21 7256 7265 1:CAS:528:DC%2BD38XnsFylu7c%3D 12370817
74. R.A. Blake M.A. Broome X. Liu, et al. 2000 SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling Mol Cell Biol 20 9018 9027 1:CAS:528:DC%2BD3MXitFGrsL8%3D 11074000
75. M. Sekharam A. Nasir H.E. Kaiser, et al. 2003 Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro Anticancer Res 23 1517 1524 1:CAS:528:DC%2BD3sXltlGmurk%3D 12820418
76. L.C. Kim L. Song E.B. Haura 2009 Src kinases as therapeutic targets for cancer Nat Rev Clin Oncol 6 587 595 19787002
77. M. Talpaz N.P. Shah H. Kantarjian, et al. 2006 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2531 2541 1:CAS:528:DC%2BD28Xlslyisb0%3D 16775234 (Pubitemid 43882349)
78. N.P. Shah C. Tran F.Y. Lee, et al. 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 399 401 1:CAS:528: DC%2BD2cXls1egtrY%3D 15256671
79. M. Lindauer A. Hochhaus 2010 Dasatinib Recent Results Cancer Res 184 83 102 20072833
80. J.G. Trevino J.M. Summy D.P. Lesslie, et al. 2006 Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model Am J Pathol 168 962 972 1:CAS:528:DC%2BD28XislGguro%3D 16507911
81. A.C. Shor E.A. Keschman F.Y. Lee, et al. 2007 Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival Cancer Res 67 2800 2808 1:CAS:528:DC%2BD2sXivV2nsb4%3D 17363602
82. A.S. Tsao D. He B. Saigal, et al. 2007 Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion Mol Cancer Ther 6 1962 1972 1:CAS:528:DC%2BD2sXnsV2jsrw%3D 17620427
83. F. Timeus N. Crescenzio A. Fandi, et al. 2008 In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines Oncol Rep 19 353 359 1:CAS:528:DC%2BD1cXitV2ks7Y%3D 18202781
84. S.I. Park J. Zhang K.A. Phillips, et al. 2008 Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model Cancer Res 68 3323 3333 1:CAS:528: DC%2BD1cXltlSlsL4%3D 18451159
85. C.S. Pichot S.M. Hartig L. Xia, et al. 2009 Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells Br J Cancer 101 38 47 1:CAS:528:DC%2BD1MXotVKgurs%3D 19513066
86. Y.L. Choi M. Bocanegra M.J. Kwon, et al. 2010 LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer Cancer Res 70 2296 2306 1:CAS:528:DC%2BC3cXjtFygt7k%3D 20215510
87. X.H. Zhang Q. Wang W. Gerald, et al. 2009 Latent bone metastasis in breast cancer tied to Src-dependent survival signals Cancer Cell 16 67 78 1:CAS:528:DC%2BD1MXhtVWnsL7I 19573813
88. M.H. Herynk A.R. Beyer Y. Cui, et al. 2006 Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells Mol Cancer Ther 5 3023 3031 1:CAS:528:DC%2BD28Xhtlagsb3E 17172405
89. J.M. Golas J. Lucas C. Etienne, et al. 2005 SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models Cancer Res 65 5358 5364 1:CAS:528:DC%2BD2MXltFelsrk%3D 15958584
90. W.A. Messersmith S. Krishnamurthi B.A. Hewes, et al. 2007 Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25 18S 3552
91. P.N. Lara Jr J. Longmate C.P. Evans, et al. 2009 A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs 20 179 184 1:CAS:528:DC%2BD1MXjtl2ntL0%3D 19396016
92. E.B. Haura T. Tanvetyanon A. Chiappori, et al. 2010 Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J Clin Oncol 28 1387 94 1:CAS:528: DC%2BC3cXksFSqur0%3D 20142592
93. A.A. Miller H. Pang L. Hodgson, et al. 2010 A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) J Thorac Oncol 5 380 384 20087228
94. E.Y. Yu G. Wilding E. Posadas, et al. 2009 Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 7421 7428 1:CAS:528:DC%2BD1MXhsFSnu7vO 19920114
95. S. Schenone F. Manetti M. Botta 2007 Synthetic SRC-kinase domain inhibitors and their structural requirements Anticancer Agents Med Chem 7 660 680 1:CAS:528:DC%2BD2sXhtlWiur%2FE 18045061
96. C. Frank C. Burkhardt D. Imhof, et al. 2004 Effective dephosphorylation of Src substrates by SHP-1 J Biol Chem 279 11375 11383 1:CAS:528: DC%2BD2cXitFyhtro%3D 14699166
97. G. Ye R. Tiwari K. Parang 2008 Development of Src tyrosine kinase substrate binding site inhibitors Curr Opin Investig Drugs 9 605 613 1:CAS:528:DC%2BD1cXotlGhtbw%3D 18516760
98. G.M. Lau G.L. Yu I.H. Gelman, et al. 2009 Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro Dig Dis Sci 54 1465 1474 1:CAS:528:DC%2BD1MXmslOktrw%3D 18979199
99. KX2-391 in treating patients with advanced solid tumors or lymphoma that did not tespond to treatment. http://clinicaltrials.gov/ct2/show/NCT00646139? term=KX2-391&rank=2
100. Evaluation of KX2-391 in patients with advanced malignancies. http://clinicaltrials.gov/ct2/show/NCT00658970?term=KX2-391&rank=3
101. A safety and efficacy study of KX2-391 in patients with bone-metastatic, castration-resistant prostate cancer who have not received prior chemotherapy. http://clinicaltrials.gov/ct2/show/NCT01074138?term=KX2-391&rank=1
102. K. Riento A.J. Ridley 2003 Rocks: multifunctional kinases in cell behaviour Nat Rev Mol Cell Biol 4 446 456 1:CAS:528:DC%2BD3sXktFOnsrc%3D 12778124
103. M. Takayasu Y. Suzuki M. Shibuya, et al. 1986 The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs J Neurosurg 65 80 85 1:CAS:528:DyaL28XkvFSqurg%3D 3712031
104. H. Ying S.L. Biroc W.W. Li, et al. 2006 The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models Mol Cancer Ther 5 2158 2164 1:CAS:528:DC%2BD28Xps1yns74%3D 16985048
105. L. Yin K. Morishige T. Takahashi, et al. 2007 Fasudil inhibits vascular endothelial growth factorinduced angiogenesis in vitro and in vivo Mol Cancer Ther 6 1517 1525 1:CAS:528:DC%2BD2sXotFaltL8%3D 17513600
106. X. Yang Y. Liu Z. Zong, et al. 2010 The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells Biomed Pharmacother 64 58 62 1:CAS:528:DC%2BC3cXnvFeh 19879105
107. S. Ogata K. Morishige K. Sawada, et al. 2009 Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells Int J Gynecol Cancer 19 1473 1480 19955921
108. L. Deng G. Li R. Li, et al. 2010 Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo Cancer Biol Ther 9 875 884 20364104
109. E.H. Mahlamaki P. Kauraniemi O. Monni, et al. 2004 High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer Neoplasia 6 432 439 1:CAS:528:DC%2BD2cXhtVShurbI 15548351
110. J.H. Kim H.N. Kim K.T. Lee, et al. 2008 Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis Tumour Biol 29 41 49 1:CAS:528:DC%2BD1cXmtFGns74%3D 18497548
111. C.M. Wells A. Abo A.J. Ridley 2002 PAK4 is activated via PI3K in HGF-stimulated epithelial cells J Cell Sci 115 3947 3956 1:CAS:528: DC%2BD38Xos12ktb4%3D 12244132
112. J. Eswaran M. Soundararajan S. Knapp 2009 Targeting group II PAKs in cancer and metastasis Cancer Metastasis Rev 28 209 217 1:CAS:528: DC%2BD1MXjsVWntrk%3D 19160016
113. M.G. Callow F. Clairvoyant S. Zhu, et al. 2002 Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines J Biol Chem 277 550 558 1:CAS:528:DC%2BD38XjslGnsQ%3D%3D 11668177
114. B.W. Murray C. Guo J. Piraino, et al. 2010 Smallmolecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth Proc Natl Acad Sci U S A 107 9446 9451 1:CAS:528: DC%2BC3cXmslWqtrw%3D 20439741
115. This is the first study using escalating doses of PF-03758309, an oral compound, in patients with advanced solid tumors. http://clinicaltrials.gov/ct2/ show/NCT00932126?term=PAK4&rank=1
116. M. Quintela-Fandino E. Arpaia D. Brenner, et al. 2010 HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1 Proc Natl Acad Sci U S A 107 2622 2627 1:CAS:528: DC%2BC3cXit1aksb0%3D 20133759